Table 1.
Patient characteristics stratified according to ESC/European Atherosclerosis Society (EAS) guideline and cardiovascular (CV) risk category (total number of patients in 2016: 98,932; total number of patients in 2019: 103,351).
| 2016 Guideline | ||||
|---|---|---|---|---|
| Patient Characteristics | Low Risk | Moderate Risk | High Risk | Very High Risk |
| (n = 9461) | (n = 21,138) | (n = 29,176) | (n = 39,157) | |
| Median age (IQR) | 47 (44–51) | 58 (53–63) | 69 (53–81) | 72 (61–81) |
| % female | 75.7 | 38.6 | 57.0 | 42.6 |
| % with an LDL-C measurement | 9.9 | 16.1 | 19.1 | 36.9 |
| median LDL-C (IQR) mmol/L | 3.1 (2.5–3.8) | 3.3 (2.7–4) | 3.0 (2.3–3.9) | 2.3 (1.8–3.1) |
| Morbidities | ||||
| s % with previous CVD | 0.0 | 0.0 | 0.0 | 27.8 |
| % with severe CKD | 0.0 | 0.0 | 0.0 | 10.2 |
| % with moderate CKD | 0.0 | 0.0 | 57.9 | 25.1 |
| % with diabetes | 0.0 | 0.0 | 23.6 | 74.2 |
| % with dyslipidemia | 53.5 | 68.7 | 32.5 | 39.8 |
| % with hypertension | 11.7 | 22.3 | 43.4 | 67.2 |
| % with obesity | 15.7 | 16.3 | 12.5 | 25.5 |
| Lipid-lowering drugs | ||||
| % no treatment | 97.6 | 93.3 | 80.0 | 52.2 |
| % statin only | 2.1 | 6.0 | 18.3 | 42.7 |
| % statin and ezetimibe | 0.18 | 0.46 | 1.37 | 4.52 |
| % ezetimibe only | 0.11 | 0.19 | 0.33 | 0.49 |
| % statin and PCSK-9 inhibitors | 0.00 | 0.00 | 0.03 | 0.06 |
| % PCSK-9 inhibitors only | 0.00 | 0.00 | 0.01 | 0.02 |
| 2019 Guideline | ||||
| Patient Characteristics | Low Risk | Moderate Risk | High Risk | Very High Risk |
| (n = 10,094) | (n = 17,583) | (n = 54,876) | (n = 20,798) | |
| Median age (IQR) | 48 (44–52) | 58 (53–62) | 68 (56–78) | 74 (66–83) |
| % female | 74.8 | 38.9 | 51.8 | 38.7 |
| % with an LDL-C measurement | 9.0 | 13.5 | 24.6 | 37.9 |
| median LDL-C (IQR) mmol/L | 3.1 (2.5–3.6) | 3.2 (2.6–3.8) | 2.9 (2.1–3.7) | 2.2 (1.7–3) |
| Morbidities | ||||
| % with previous CVD | 0.0 | 0.0 | 0.0 | 52.4 |
| % with severe CKD | 0.0 | 0.0 | 0.0 | 19.1 |
| % with moderate CKD | 0.0 | 0.0 | 36.8 | 31.5 |
| % with diabetes | 0.0 | 0.0 | 47.9 | 46.4 |
| % with dyslipidemia | 52.2 | 67.0 | 38.5 | 48.1 |
| % with hypertension | 10.8 | 22.7 | 45.4 | 78.6 |
| % with obesity | 14.9 | 16.9 | 15.4 | 29.8 |
| Lipid-lowering drugs | ||||
| % no treatment | 98.0 | 94.2 | 74.6 | 42.2 |
| % statin only | 1.8 | 5.3 | 23.4 | 50.5 |
| % statin and ezetimibe | 0.11 | 0.39 | 1.61 | 6.63 |
| % ezetimibe only | 0.09 | 0.15 | 0.38 | 0.60 |
| % statin and PCSK-9 inhibitors | 0.00 | 0.00 | 0.02 | 0.12 |
| % PCSK-9 inhibitors only | 0.00 | 0.01 | 0.01 | 0.04 |
IQR: interquartile range; LDL-C: low-density lipoprotein cholesterol; CVD: cardiovascular disease; CKD: chronic kidney disease; PCSK-9: proprotein convertase subtilisin/kexin-9.